Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted
Thesis Summary

Aemetis is transitioning from a capital-intensive project buildout phase to a recurring, high-margin monetization phase. The investment thesis is anchored on three major near-term catalysts: the monetization of stacked environmental credits (specifically Section 45Z and LCFS pathways), the commissioning of the Mechanical Vapor Recompression (MVR) system at the Keyes plant to drive $32 million in annual cash flow, and the planned summer 2026 IPO of its India biodiesel subsidiary to dramatically improve liquidity and facilitate the refinancing of expensive short-term debt.

Sign in / Sign up to read more
This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.
Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026
Low · most bearish analyst$2.50
Mean target$13.88
High · most bullish analyst$28.00
Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026
Scenarios · 12-month scenario targetsAnchored at research date
Bear CaseDownside scenario
$2.5020%

Delays in the India IPO and failure to refinance the $342.6 million in current/on-demand debt, leading to severe liquidity constraints or dilutive equity issuances. Regulatory delays in DOE's 45Z GREET model updates or lower LCFS credit pricing further depress margins.

Base CaseCentral scenario
$13.8855%
Matches the consensus mean

Steady execution of the Keyes MVR system commissioning by late 2026, gradual ramp-up of Dairy RNG volumes, and a completed India IPO that provides sufficient liquidity to address immediate debt maturities. Section 45Z tax credits continue to support gross margin improvements.

Bull CaseUpside scenario
$28.0025%

Rapid regulatory approvals of additional provisional LCFS pathways combined with a successful, high-valuation India IPO in summer 2026. This allows the company to fully refinance its high-interest US debt, eliminate going concern warnings, and accelerate the construction of its 78 million gallon Sustainable Aviation Fuel (SAF) and Renewable Diesel plant.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits
  • Stacked credit monetization including Section 45Z credits ($4.0 million recognized in Q1 2026) and high-value provisional LCFS pathways (average CI score of negative 380).
  • Keyes plant MVR upgrade is highly advanced, with major equipment on-site, expected to displace 80% of natural gas usage and generate $32 million in annual cash flow.
  • The planned India IPO of Universal Biofuels serves as a major non-dilutive liquidity catalyst to transform the global balance sheet.
Sign in / Sign up to read more
Key Investment Risks
  • Severe balance sheet risk with $404.7 million in total debt, of which $342.6 million is classified as current or due on demand, triggering going concern warnings.
  • High dependency on regulatory timelines, specifically the Department of Energy's publication of the updated 45Z GREET calculator.
  • Execution risk surrounding the timing and valuation of the India subsidiary IPO.
Sign in / Sign up to read more
Thesis Invalidation Triggers
  1. Cancellation or indefinite postponement of the Universal Biofuels IPO in India.
  2. Failure to refinance or extend near-term debt facilities, leading to technical defaults or highly dilutive emergency equity financing.
  3. Adverse changes to federal Section 45Z tax credit guidelines or a collapse in LCFS credit pricing.
Sign in / Sign up to read more

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Explore this dossier

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.